<DOC>
	<DOCNO>NCT01176747</DOCNO>
	<brief_summary>The purpose study investigate lung deposition distribution pattern Beclometasone Formoterol use gamma-scintigraphic technique inhalation single dose 99mTc-radiolabelled BDP/formoterol fix combination administer Via NEXT DPI healthy volunteer , asthmatic COPD patient . Additionally , systemic exposure formoterol , BDP monopropionate metabolite ( B17MP ) investigate .</brief_summary>
	<brief_title>Lung Deposition BDP/Formoterol Combination Administered Via NEXT DPI Healthy , Asthmatic COPD Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Healthy volunteer : Males female age 1865 year ; Body Mass Index ( BMI ) 18.0 28.0 kg/m2 ; Non exsmokers smoke &lt; 5 pack year stop smoke &gt; 1 year ; Normal blood pressure heart rate ; Normal electrocardiogram ( ECG,12 lead ) ; Normal laboratory test ; Patients Asthma : Males female age 2165 year ; BMI 18.0 28.0 kg/m2 ; Non exsmokers smoke &lt; 5 pack year stop smoke &gt; 1 year ; Normal blood pressure heart rate ; Normal ECG ( 12 lead ) ; FEV1 ≥ 30 % &lt; 80 % predict accord European Coal Steel Community value ( ECSC ) Reversibility FEV1 ≥ 12 % least 200 ml initial value 15 minute inhalation 200 µg Salbutamol ; Patients COPD : Males female age 40 70 year BMI 18.0 30.0 kg/m2 ; Normal blood pressure heart rate ; Normal ECG ( 12 lead ) ; Stable COPD within past 4 week ; Post bronchodilator FEV1 30 % 50 % predict value ( ECSC ) ; Post bronchodilator FEV1/FVC &lt; 0.70 ( absolute value ) ; Minimum smoking history 10 packyears ; All subject : Blood donation blood loss previous 8 week ; Positive HIV1 HIV2 serology ; Positive acute chronic Hepatitis B Hepatitis C ; Unsuitable vein repeat venipuncture ; Female patient : pregnant , positive pregnancy test , lactate mother lack efficient contraception . History substance abuse positive urine drug screen ; Abnormal laboratory value suggest unknown disease require clinical investigation ; Uncontrolled cardiac , hepatic , renal , gastrointestinal , endocrine , metabolic , neurologic , psychiatric clinically significant disorder ; Participation another clinical trial previous 8 week ; participation study use radioactive material within 1 calendar year ; Known sensitivity Formoterol Beclometasone excipients ; Concomitant severe disease diseases contra indication use inhaled Beta2agonist steroid ; Use prescription drug concomitant betaagonist steroid administration contraindicate ; Recent relevant infectious disease ( less two month ) ; Flu vaccination vaccination within 4 week prior screen visit ; Additional exclusion criterion healthy volunteer : Lung function measurement outside normal limit ( normal value : FEV1/FVC &gt; 0.70 FEV1 FVC &gt; 80 % ECSC predict value ) ; Additional exclusion criterion patient Asthma : Use systemic steroid 4 week prior inclusion ( injectable depot steroid 6 week ) 3 period last 6 month ; Lifethreatening/unstable respiratory status within previous 30 day ; Requirement supplemental oxygen therapy ; Change dose type medication asthma within 4 week prior screen visit ; Asthma exacerbation within 4 week prior inclusion . Additional exclusion criterion patient COPD : Use systemic steroid 4 week prior inclusion ( injectable depot steroid 6 week ) 3 period last 6 month ; Lifethreatening/unstable respiratory status within previous 30 day ; Requirement supplemental oxygen therapy ; Change dose type medication COPD within 4 week prior screen visit ; COPD exacerbation within 4 week prior inclusion ; History asthma chronic respiratory disease COPD .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>